The comparison of Carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after a 2nd-line therapy in relapsed and refractory multiple myeloma patients

Abstract

New class of drugs are emerging in heavily pretreated patients in clinical trials, carfilzomib, and dexamethasone (Kd) and pomalidomide and dexamethasone with or without cyclophosphamide (Pd or PCd) are still important options for treatment of relapsed and/or refractory multiple myeloma (RRMM). However, direct comparison of the efficacy of carfilzomib and pomalidomide has not been evaluated. The aim of this study was to compare the efficacy and safety profile of Kd and pom-based regimens in RRMM patients after 2nd line chemotherapy in the real world clinical setting. Patient and method: Two-hundred and twenty-five patients from 14 hospitals participating in the Korean multiple myeloma working party (KMMWP) were retrospectively analyzed by review of medical records. Multiple myeloma patients who relapsed or were refractory to 2 or more lines of chemotherapy regimens and who had been treated with Kd (Kd group, N=44) or pomalidomide-based chemotherapy (Pom group, N=181) were included. When patients who had been administered with both carfilzomib and pomalidomide-combination chemotherapies sequentially, the drug used in advance was analyzed. The pomalidomide group included patients who had undergone Pd (N=108) and PCd (N=73).